Figure 4.
Figure 4. RQ-PCR for CARMA1 and correlation of genomic amplification. RQ-PCR was used to detect the expression level of CARMA1 in ATLL patients with or without 7p22 gain/amplification. Twenty lymphoma-type cases were divided into 2 groups, 1 group with copy number gain/amplification (gain +) and the other group without any copy number change (gain –). The top panels show expression levels of CARMA1 determined by RQ-PCR, while the bottom panels indicate genomic profiles determined by array CGH. The horizontal dotted line in the top left panel in the gain group indicates the mean value (0.603) of the expression level (SD, 0.312). Four patients with acute-type ATLL are represented in the center panels. For comparison, 1 sample of CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) and 2 samples of PBMCs were examined by RQ-PCR (right panels).

RQ-PCR for CARMA1 and correlation of genomic amplification. RQ-PCR was used to detect the expression level of CARMA1 in ATLL patients with or without 7p22 gain/amplification. Twenty lymphoma-type cases were divided into 2 groups, 1 group with copy number gain/amplification (gain +) and the other group without any copy number change (gain –). The top panels show expression levels of CARMA1 determined by RQ-PCR, while the bottom panels indicate genomic profiles determined by array CGH. The horizontal dotted line in the top left panel in the gain group indicates the mean value (0.603) of the expression level (SD, 0.312). Four patients with acute-type ATLL are represented in the center panels. For comparison, 1 sample of CD4+ T cells isolated from peripheral blood mononuclear cells (PBMCs) and 2 samples of PBMCs were examined by RQ-PCR (right panels).

Close Modal

or Create an Account

Close Modal
Close Modal